N-Olaparib

Our research focuses on the development of new drugs for the treatment of colon cancer, metabolic and neurodegenerative diseases.

VIEW FEATURES

N-Olaparib

Therapeutic area

Oncology

Target disease

Pancreatic cancer

Study phase

Preclinical: In vitro

100%

Preclinical: In vivo

100%

Clinic I

Not initiated

Clinic II

Not initiated

Clinic III

Not initiated

International Application:

P202231095

Scientific Publication:

Olaparib reduces the lethality of pancreatic cancer cells and increases their sensitivity to Gemcitabine

Discover the Future

We are a biotechnology company committed to the discovery of efficient and effective bioactive principles as pharmaceuticals, nutraceuticals or useful in the field of plant biology.